Depression in Parkinson's disease. Pharmacological characteristics and treatment

Drugs and Aging

Volumn 12, Issue 1, 1998, Pages 55-74

  Tom, Tiffany ^a,b   Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CATECHOLAMINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AKINESIA; ANXIETY; DEPRESSION; DISABILITY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEROTONIN SYNDROME; SEX DIFFERENCE; TRANSCRANIAL MAGNETIC STIMULATION;

AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HUMANS; PARKINSON DISEASE;

EID: 0031983225     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812010-00006     Document Type: Review

References (137)

1. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol 1992; 49: 492-7
2. Adams RD, Victor M. Principles of neurology. 4th ed. New York: McGraw-Hill, 1989
3. Harvey NS. Psychiatric disorders in parkinsonism: I. Functional illnesses and personality. Psychosomatics 1986; 27: 91-103
4. Friedenberg DL, Cummings JL. Parkinson's disease, depression, and the on-off phenomenon. Psychosomatics 1989; 30: 94-9
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1984
6. Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson's disease: a community-based study. Arch Neurol 1996; 53: 175-9
7. Rodin G, Voshart K. Depression in the medically ill: an overview. Am J Psychiatry 1986; 143: 695-705
8. Santamaria J, Tolosa E. Clinical subtypes of Parkinson's disease and depression. In: Huber SJ, Cummings JL, editors. Parkinson's disease: neurobehavioral aspects. New York: Oxford University Press, 1992: 217-8
9. Santamaria J, Tolosa E, Valle A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130-3
10. Cole SA, Woodard JL, Juncos JL, et al. Depression and disability in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8: 20-5
11. Kostic VS, Filipovic SR, Lecic D, et al. Effect of age at onset on frequency of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 1265-7
12. Starkstein SE, Berthier ML, Bolduc PL, et al. Depression in patients with early versus late onset of Parkinson's disease. Neurology 1989; 39: 1441-5
13. Wagner ML, Fedak MN, Sage JI, et al. Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Ann Clin Lab Sci 1996; 26: 389-95
14. Gibb WRG, Lees AJ. A comparison of clinical and pathological features of young-and old-onset Parkinson's disease. Neurology 1988; 38: 1402-6
15. Taylor AE, Saint-Cyr JA. Depression in Parkinson's disease: reconciling physiological and psychological perspectives. J Neuropsychiatry Clin Neurosci 1990; 2: 92-8
16. Brown R, Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. Adv Neurol 1995; 65: 61-84
17. Miyoshi K, Ueki A, Nagano O. Management of psychiatric symptoms of Parkinson's disease. Eur Neurol 1996; 36 Suppl. 1: 49-54
18. Henderson S. Epidemiology of psychiatric disorders. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry. 6th ed. Baltimore: Williams and Wilkins, 1995: 2513-9
19. Barber J, Tomer R, Sroka H, et al. Does unilateral dopamine deficit contribute to depression? Psychiatry Res 1985; 15: 17-24
20. Vogel H-P. Symptoms of depression in Parkinson's disease. Pharmacopsychiatry 1982; 15: 192-6
21. Cummings JL. Neuropsychiatric complications of drug treatment of Parkinson's disease. In: Huber SJ, Cummings JL, editors. Parkinson's disease: neurobehavioral aspects. New York: Oxford University Press, 1992: 313-27
22. Shaw AM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Q J Med 1980; 49: 283-93
23. Goodwin FK. Behavioral effects of L-dopa in man. Semin Psychiatry 1971; 3: 477-92
24. Silver JM, Yudofsky SC. Drug treatment of depression in Parkinson's disease. In: Huber SJ, Cummings JL, editors. Parkinson's disease: neurobehavioral aspects. New York: Oxford University Press, 1992: 240-54
25. Cherington M, Parkinsonism, L-dopa and mental depression. J Am Geriatr Soc 1970; 18: 513-6
26. Schiffer RB, Kurlan R, Rubin A, et al. Evidence for atypical depression in Parkinson's disease. Am J Psychiatry 1988; 145: 1020-2
27. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8: 383-92
28. Factor SA, Molho ES, Podskalny GD, et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995; 65: 115-38
29. Menza MA, Rosen RC. Sleep in Parkinson's disease: the role of depression and anxiety. Psychosomatics 1995; 36: 262-6
30. Tandberg E, Larsen JP, Aarsland D, et al. Risk factors for depression in Parkinson disease. Arch Neurol 1997; 54: 625-30
31. Troester AI, Paolo AM, Lyons KE, et al. The influence of depression on cognition in Parkinson's disease: a pattern of impairment distinguishable from Alzheimer's disease. Neurology 1995; 45: 672-5
32. Troester AI, Stalp LD, Paolo AM, et al. Neuropsychological impairment in Parkinson's disease with and without depression. Arch Neurol 1995; 52: 1164-9
33. Kuzis G, Sabe L, Tiberti C, et al. Cognitive functions in major depression and Parkinson disease. Arch Neurol 1997; 54: 982-6
34. Wertman E, Speedie L, Shemesh Z, et al. Cognitive disturbances in parkinsonian patients with depression. Neuropsych Neuropsychol Behav Neurol 1993; 6: 31-7
35. Taylor AE, Saint-Cyr JA, Lang AE, et al. Parkinson's disease and depression. Brain 1986; 109: 279-92
36. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149: 443-54
37. Keshavan MS, David AS, Narayanen HS, et al. 'On-off' phenomena and manic-depressive mood shifts: case report. J Clin Psychiatry 1986; 47: 93-4
38. Sandyk R. Locus ceruleus-pineal melatonin interactions and the pathogenesis of the 'on-off' phenomenon associated with mood changes and sensory symptoms in Parkinson's disease. Int J Neurosci 1989; 49: 95-101
39. Mayberg HS, Starkstein SE, Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990; 28: 57-64
40. Bissessur S, Tissingh G, Wolters EC, et al. rCBF SPECT in Parkinson's disease patients with mental dysfunction. J Neural Transm Suppl 1997; 50: 25-30
41. Ring HA, Bench CJ, Trimble MR, et al. Depression in Parkinson's disease: a positron emission study. Br J Psychiatry 1994; 165: 333-9
42. Starkstein SE, Mayberg HS, Leiguarda R, et al. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 377-82
43. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
44. Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease: proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994; 89: 242-51
45. de Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson's disease. Neurology 1997; 48: 1277-81
46. Sano M, Mayeux R. Biochemistry of depression in Parkinson's disease. In: Huber SJ, Cummings JL, editors. Parkinson's disease: neurobehavioral aspects. New York: Oxford University Press, 1992: 229-39
47. Mayeux R, Stern Y, Williams JBW, et al. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986; 143: 756-9
48. Frochtengarten ML, Villares JCB, Maluf E, et al. Depressive symptoms and the dexamethasone suppression test in parkinsonian patients. Biol Psychiatry 1987; 22: 386-9
49. Rabey JM, Schart M, Oberman Z, et al. Cortisol, ACTH, and beta-endorphin after dexamethasone administration in Parkinson's dementia. Biol Psychiatry 1990; 27: 581-91
50. Mayberg HS, Solomon DH. Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol 1995; 65: 49-60
51. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology 1980; 30: 1326-30
52. Fibiger HC. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci 1984; 11: 105-7
53. Cantello R, Aguggia M, Gilli M, et al. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the 'hedonic' dopamine synapse. J Neurol Neurosurg Psychiatry 1989; 52: 724-31
54. Mayeux R, Stern Y, Cote L, et al. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34: 642-6
55. Mayeux R, Stern Y, Sano M, et al. The relationship of serotonin to depression in Parkinson's disease. Mov Disord 1988; 3: 237-44
56. Wolfe N, Katz DI, Albert ML, et al. Neuropsychological profile linked to low dopamine in Alzheimer's disease, major depression, and Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 915-7
57. Sano M, Stern Y, Cote L, et al. Depression in Parkinson's disease: a biochemical model. J Neuropsychiatry Clin Neurosci 1990; 2: 88-92
58. Schneider LS, Chui HC, Severson JA, et al. Decreased platelet 3H-imipramine binding in Parkinson's disease. Biol Psychiatry 1988; 24: 348-51
59. Cash R, Raisman R, Ploska A, et al. High and low affinity [3H]imipramine binding sites in control and parkinsonian brains. Eur J Pharmacol 1985; 117: 71-80
60. D'Amato RJ, Zweig RM, Whitehouse PJ, et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1986; 22: 229-36
61. Raisman R, Cash R, Agid Y. Parkinson's disease: decreased density of 3H-imipraminc and 3H-paroxetine binding sites in putamen. Neurology 1986; 36: 556-60
62. Mena MA, Aguado EG, de Yebenes JG. Monoamine metabolites in human cerebrospinal fluid: HPLC/ED method. Acta Neurol Scand 1984; 69: 218-25
63. Kostic VS, Djuricic BM, Covickovic-Sternic N, et al. Depression and Parkinson's disease: possible role of serotonergic mechanisms. J Neurol 1987; 234: 94-6
64. Chia LG, Cheng FC, Kuo JS. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. J Neurol Sci 1993; 116: 125-34
65. Bell IR, Amend D, Kaszniak AW, et al. Trait shyness in the elderly: evidence for an association with Parkinson's disease in family members and biochemical correlates. J Geriatr Psychiatry Neurol 1995; 8: 16-22
66. Menza MA, Mark MH. Parkinson's disease and depression: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci 1993; 6: 165-9
67. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locas coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989; 287: 373-92
68. Chan-Palay V. Depression and dementia in Parkinson's disease: catecholamine changes in the locus ceruleus, a basis for therapy. Adv Neurol 1993; 60: 438-46
69. Mindham RHS, Marsden CD, Parkes JD. Psychiatric symptoms during L-dopa therapy for Parkinson's disease and their relationship to physical disability. Psychol Med 1976; 6: 23-33
70. Jouvent R, Abensour P, Bonnet AM, et al. Antiparkinsonian and antidepressant effects of high doses of bromocriptine. J Affect Disord 1983; 5: 141-5
71. Muscat R, Papp M, Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry 1992; 31: 937-46
72. Moryl E, Danysz W, Quack G. Potential antidepressive propertics of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993; 72: 394-7
73. Huszonek JJ. Anticholinergic effects in a depressed parkinsonian patient. J Geriatr Psychiatry Neurol 1995; 8: 100-2
74. Kuhn W, Muller T. The clinical potential of deprenyl in neurologic and psychiatric disorders. J Neural Transm Suppl 1996; 48: 85-93
75. Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolised to methamphetamine and amphetamine in man. Br J Clin Pharmacol 1978; 6: 542-4
76. Baronti F, Davis TL, Boldry RC, et al. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992; 42: 541-4
77. Brown AS, Gershon S. Dopamine and depression. J Neural Transm 1993; 91: 75-109
78. Parkinson Study Group. Effect of deprenyl of the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-71
79. Przuntek H, Kuhn W, Kraus P. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarhoxylase inhibitor correlated to depression and MHPG, HIAA, and HVA levels in the cerehrospinal fluid. Acta Neurol Scand Suppl 1989; 126: 153-6
80. Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo parkinsonian patients: the French Selegiline Multicenter Trial. Mov Disord 1993; 8 Suppl. 1: S36-40
81. Hoffman WF. Treatment of major depression and Parkinson's disease with combined phenelzine and amantadine [letter]. Am J Psychiatry 1985; 142: 273
82. Hargrave R, Ashford JW. Phenelzine treatment of depression in Parkinson's disease. Am J Psychiatry 1992; 149: 1751-2
83. Lavian G, Finberg JPM, Youdim MBH. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine. Clin Neuropharmacol 1993; 16 Suppl. 2: S1-7
84. Haefely W, Burkard WP, Cesura A, et al. Pharmacology of moclobemide. Clin Neuropharmacol 1993; 16 Suppl. 2: S8-18
85. Waldmeier PC, Glatt A, Jaekel J, et al. Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor. Clin Neuropharmacol 1993; 16 Suppl. 2: S19-24
86. Mannisto PT, Lang A, Rauhala P, et al. Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. Eur J Pharmacol 1995; 274: 229-33
87. Illi A, Sundberg S, Ojala-Karlsson P, et al. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996; 59: 450-7
88. Klockgether T, Loschmann PA, Wullner U. New medical and surgical treatments for Parkinson's disease. Curr Opin Neurol 1994; 7 (4): 346-52
89. Price LH, Spencer DD, Marek KL, et al. Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. Biol Psychiatry 1995; 38: 498-505
90. Masterman DL, Bronstein J, DeSalles AF, et al. Cognitive and behavioral performance following unilateral ventroposterior pallidotomy. Neurology 1997; 48: A252-3
91. Warburton JW. Depressive symptoms in Parkinson's patients referred for thalamotomy. J Neurol Neurosurg Neuropsychiatry 1967; 30: 368-70
92. Klaassen T, Verhey FRJ, Sneijders GHJM, et al. Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995; 7: 281-6
93. Mandell AJ, Markham C, Fowler W. Parkinson's syndrome, depression and imipramine: a preliminary report. Calif Med 1961; 95: 12-4
94. Denmark JC, David JDP, McComb SG. Imipramine hydrochloride (Tofranil) in parkinsonism: a preliminary report. Br J Clin Pract 1961; 15: 523-4
95. Gillhespy RO, Mustard DM. The evaluation of imipramine in the treatment of Parkinson's disease. Br J Clin Pract 1963; 17: 205-8
96. Strang RR. Imipramine in treatment of parkinsonism: a double-blind placebo study. BMJ 1965; 2: 33-4
97. Cunningham LA. Depression in the medically ill: choosing an antidepressant. J Clin Psychiatry 1994; 55 Suppl. A: 90-7: discussion 98-100
98. Drevets WC. Geriatric depression: brain imaging correlates and pharmacologic considerations. J Clin Psychiatry 1994; 55 Suppl. A: 71-81; discussions 82, 98-100
99. Stoudemire A. New antidepressant drugs and the treatment of depression in the medically ill patient. Psychiatr Clin North Am 1996; 19: 495-514
100. McCance-Katz EF, Marek KL, Price LH. Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 1992; 42: 1813-4
101. Steur ENHJ. Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211-3
102. Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson's disease, and the locus ceruleus. Clin Neuropharmacol 1986; 9: 373-8
103. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994; 55: 234-41
104. Montgomery SA. Efficacy in long-term treatment of depression. J Clin Psychiatry 1996; 57 Suppl. 2: 24-30
105. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 25-35
106. Marttila M, Jaaskelainen J, Jarvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995; 5: 441-6
107. Goetz CG. Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 1984; 34: 1092-4
108. Preskorn SH, Othmer SC. Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy 1984; 4: 20-34
109. Martin P, Massol J, Puech AJ. Captopril as an antidepressant? Effects on the learned helplessness paradigm in rats. Biol Psychiatry 1990; 27: 968-74
110. Khawaja AM, Rogers DF. Tachykinins: receptor to effector. Int J Biochem Cell Biol 1996; 28: 721-38
111. Rasmussen KG, Abrams R. The role fit electroconvulsive therapy in Parkinson's disease. In: Huber SJ, Cummings JL, editors. Parkinson's disease: neurobehavioral aspects. New York: Oxford University Press, 1992: 255-70
112. Atre-Vaidya N, Jampala VC. Electroconvulsive therapy in parkinsonism with affective disorder. Br J Psychiatry 1988; 152: 55-8
113. Douyon R, Serby M, Klutchko B, et al. ECT and Parkinson's disease revisited: a 'naturalistic' study. Am J Psychiatry 1989; 146: 1451-5
114. Holcomb HH, Sternberg DE, Heninger GR. Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine systems. Biol Psychiatry 1983; 18: 865-73
115. Lebensohn ZM, Jenkins RB. Improvement of parkinsonism in depressed patients treated with ECT. Am J Psychiatry 1975; 132: 283-385
116. Asnis G. Parkinson's disease, depression, and ECT: a review and case study. Am J Psychiatry 1977; 134: 191-5
117. Burke WJ, Peterson J, Rubin EH. Electroconvulsive therapy in the treatment of combined depression and Parkinson's disease. Psychosomatics 1988; 29: 341-6
118. Balldin J, Granerus A, Linstedt G, et al. Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms. J Neural Transm 1981; 52: 199-211
119. Fromm GH. Observations on the effect of electroshock treatment on patients with parkinsonism. Bull Tulane Univ 1959; 18: 71-3
120. Faber R, Trimble MR. Electroconvulsive therapy in Parkinson's disease and other movement disorders. Mov Disord 1991; 6: 293-303
121. Figiel GS, Hassen MA, Zorumski C, et al. ECT-induced delirium in depressed patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1991; 3: 405-11
122. Figiel GS, Coffey CE, Djang WT, et al. Brain magnetic resonance imaging findings in ECT-induced delirium. J Neuropsychiatry Clin Neurosci 1990; 2: 53-8
123. George MS, Wassermann EM, Post RM. Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. J Neuropsychiatry Clin Neurosci 1996; 8: 373-82
124. Sandyk R, Derpapas K. The effects of external picoTesla range magnetic fields on the EEG in Parkinson's disease. Int J Neurosci 1993; 70: 85-96
125. Fischer PA, Baas H. Therapeutic efficacy of R-(-) deprenyl as adjuvant therapy in advanced parkinsonism. J Neural Transm Suppl 1987; 25: 137-47
126. Lees A, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977; 11: 791-5
127. Hietanen MH. Selegiline and cognitive function in Parkinson's disease. Acta Neurol Scand 1991; 84: 407-10
128. Indaco A, Carrieri PD. Amitriptyline in the treatment of headache in patients with Parkinson's disease. Neurology 1988; 38: 1720-2
129. Boer BH, Erdman RAM, Onstenk HJVC, et al. Clomipramine, depresie en de ziekte van Parkinson. Tijdschr Psychiatr 1976; 28: 499-509
130. Laitinen L. Desipramine in treatment of Parkinson's disease. Ada Neurol Scand 1969; 45: 109-13
131. Bedard P, Parkes JD, Marsden CD. Nomifensine in Parkinson's disease. Br J Clin Pharmacol 1977; 4 Suppl. 2: 187S-90S
132. Andersen J, Aabro E, Gulmann N, et al. Anti-depressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 1980; 62: 210-9
133. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined used of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997; 48: 1070-7
134. Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry 1997; 9: 7-13
135. King SA. Pain in depression and Parkinson's disease [letter]. Am J Psychiatry 1993, 150: 353-4
136. Mayeux R, Williams JB, Stern Y, et al. Depression and Parkinson's disease. Adv Neurol 1984; 40: 241-50
137. Mann JJ, Aurons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989; 46: 45-50